RJA
LJPC

Raymond James & Associates’s La Jolla Pharmaceutical Company LJPC Stock Holding History

Raymond James & Associates’s Portfolio LJPC Stock Details LJPC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-8,657
Closed -$253K – 3819
2018
Q2 		$253K Sell
8,657
-86
-1% -$2.65K ﹤0.01% 3123
2018
Q1 		$260K Sell
8,743
-32,133
-79% -$1.04M ﹤0.01% 2984
2017
Q4 		$1.31M Sell
40,876
-3,200
-7% -$105K ﹤0.01% 1968
2017
Q3 		$1.53M Buy
+44,076
New +$1.42M ﹤0.01% 1826

Other funds holding LJPC

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Raymond James & Associates's LJPC Position: Q3 2018 in Review

Raymond James & Associates sold out of La Jolla Pharmaceutical Company (LJPC) in Q3 2018, closing a stake of 8,657 shares — an estimated $253K sold.

Raymond James & Associates first reported a position in LJPC in Q3 2017 and held it in 4 quarters. The position peaked at $1.53M in Q3 2017. 78 funds tracked by Wall St. Rank hold LJPC as of Q3 2018.

  • Raymond James & Associates reported no remaining La Jolla Pharmaceutical Company position as of Q3 2018 after selling out during the quarter.
  • Raymond James & Associates sold 8,657 La Jolla Pharmaceutical Company shares in Q3 2018, an estimated $253K.
  • Raymond James & Associates first reported a position in La Jolla Pharmaceutical Company in Q3 2017 and held it in 4 quarters.
  • Raymond James & Associates's La Jolla Pharmaceutical Company position peaked at $1.53M in Q3 2017.
  • 78 funds tracked by Wall St. Rank held La Jolla Pharmaceutical Company as of Q3 2018.

Based on Raymond James & Associates's 13F filing for Q3 2018, filed 14 Nov 2018.